1U5.F WAVE LIFE SCIENCES LTD.

Healthcare Biotechnology Frankfurt Exchange
4.92 EUR
Close of Nov 11, 2026
2.56 17.80
Market cap
EUR 969M
P/E
-
P/B
1.63x
ROE
-52.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 1U5.F undervalued?

Graham number

The Graham number of WAVE LIFE SCIENCES LTD. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

WAVE LIFE SCIENCES LTD. fundamental analysis

No fundamental analysis for WAVE LIFE SCIENCES LTD. yet.

WAVE LIFE SCIENCES LTD. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About WAVE LIFE SCIENCES LTD.

Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver…

Full company profile